HIF-prolyl-4-hydroxylases Inhibitors
1 drugsAbout HIF-prolyl-4-hydroxylases
HIF-prolyl-4-hydroxylases (HIF-PHs) are non-heme iron-containing dioxygenases regulating hypoxia-inducible factors (HIFs), which control cellular response to low oxygen. HIF-PHs hydroxylate HIF-alpha subunits, marking them for degradation under normal oxygen conditions. Inhibiting HIF-PHs stabilizes HIF-alpha, mimicking hypoxia and influencing angiogenesis, erythropoiesis, and glucose metabolism.
HIF-PH inhibition has therapeutic potential by mimicking the cellular response to hypoxia. Currently, there is no genetic evidence directly linking HIF-PHs to specific diseases, but modulation of HIF pathways shows promise. This suggests potential applications in conditions like anemia associated with chronic kidney disease and potentially even cancer.
VAFSEO is the only FDA-approved drug targeting HIF-PHs, with two indications. It is a small molecule drug developed by Akebia, approved in 2024. This represents a new avenue for therapeutic intervention by manipulating the body's natural response to oxygen deprivation.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Nonintubated Acute Respiratory Distress Syndrome (ARDS) with only 1 trials.
Top Drugs
Akebia is the only company with an approved drug targeting HIF-PHs.
Limited competition provides an opportunity for new entrants, but also indicates potential challenges.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets HIF-prolyl-4-hydroxylases, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Clinical Trials 46 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 18 | 17 | 0 | 1 | 100% |
| Phase 2 | 10 | 6 | 2 | 2 | 75% |
| Phase 3 | 15 | 9 | 3 | 3 | 75% |
| Phase 4 | 3 | 1 | 1 | 1 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved HIF-prolyl-4-hydroxylases drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting HIF-prolyl-4-hydroxylases. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2024 - 2024)
The first drug, VAFSEO, was approved in 2024, marking the beginning of this target class.
Early stage of target class lifecycle suggests high growth potential but also increased regulatory scrutiny.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 35 clinical trials targeting HIF-prolyl-4-hydroxylases.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities